FilingSEC EDGAR8-K
Upstream Bio Announces Phase 3 Development Plans for Verekitug
· SEC accepted
StagePhase 3 Planning
Filing content
Upstream Bio plans to initiate Phase 3 clinical trials for verekitug in severe asthma and CRSwNP in the first quarter of 2027.
AI summary of the filing. Please also check the source.Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…